Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma

Blood Cancer J. 2021 May 17;11(5):95. doi: 10.1038/s41408-021-00485-5.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / adverse effects
  • Cytarabine / therapeutic use*
  • Female
  • Humans
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Leucovorin / adverse effects
  • Leucovorin / therapeutic use*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Male
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Rituximab / adverse effects
  • Rituximab / therapeutic use*
  • Survival Analysis

Substances

  • Cytarabine
  • Rituximab
  • Lenalidomide
  • Leucovorin
  • Methotrexate